Selective Inhibitors of Nuclear Exports—A Novel Anti-Cancer Drug Class: The Review Study

Abstract

For the maintenance of cell homeostasis nucleus-cytoplasmic transport is of great concern. The transport is basically depending on a size of molecule. In different hematological and solid malignancies, the CRM1 is overexpressed so the agents are requiring that particularly inhibit the exportins of nuclear export. This concept favors the SINEs development. The objective of this review study is to understand all about the novel anticancer drugs and their uses in various hematological and solid tumors. The data is carefully extracted from literature review studies of PubMed specifically. On the basic consideration of the studies, it was concluded that SINEs have a very progressive antitumor activities and it shows less interaction with drugs. However, it has synergism edicts along with other anticancer agents, so that they treat disease easily and on early basis as well e.g. combination of BRAF inhibitors/MEK inhibitors/SINEs for treating the breast cancer. The first drug that represents a novel anticancer class was Selinaxor (KPT-330).

Keywords: Nuclear export, SINEs, KPT-330, Selinaxor, various malignancies

Cite this Article

Maria Ayub, Soofia Islam, Qurat-ul-Ainriaz et al. Selective Inhibitors of Nuclear Exports—A Novel Anti-Cancer Drug Class: The Review Study. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2018; 5(1): 29–36p.